Lorraine J Gudas

US Patent:

6706506, Mar 16, 2004

Filed:

Jul 23, 2001

Appl. No.:

09/911343

Inventors:

Lorraine J. Gudas - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12Q 168

US Classification:

435183, 436 64, 435 6

Abstract:

Epithelial cell cancers and precancerous conditions are detected by assaying for LRAT expression. Failure to detect LRAT expression indicates presence of cancer, and detection of lower than normal level of LRAT expression indicates a precancerous condition.

US Patent:

7604947, Oct 20, 2009

Filed:

Jun 8, 2005

Appl. No.:

11/148149

Inventors:

Lorraine J. Gudas - New York NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

G01N 33/53
C07K 16/00

US Classification:

435 71, 5303871, 5303877

Abstract:

The invention relates to method for detecting and modulating the expression and activity of REX-1. As described herein, REX-1 is expressed in certain cancer cells, including cancer stem cells. The invention also provides methods for detecting and/or treating cancer.

US Patent:

20020183388, Dec 5, 2002

Filed:

Feb 1, 2002

Appl. No.:

10/061101

Inventors:

Lorraine Gudas - New York NY, US
David Nanus - New Rochelle NY, US

International Classification:

A61K031/203
A61K031/19
A61K031/16

US Classification:

514/559000, 514/557000, 514/575000

Abstract:

The present invention provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of trichostatin A (TSA) to an animal in need of such treatment. The present invention also provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of a histone deacetylase inhibitor and a retinoid to an animal in need of such treatment. Examples of solid tumors which may be treated using the methods of the invention include but are not limited to carcinomas of the head and neck, breast, skin, kidney, oral cavity, colon, prostate, pancreas and lung.

US Patent:

61504211, Nov 21, 2000

Filed:

Jun 2, 1998

Appl. No.:

9/088770

Inventors:

Lorraine Gudas - New York NY
Fadila Derguini - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 3112
A61K 3111

US Classification:

514690

Abstract:

Certain retinoids with CH. sub. 2 OH at the side chain terminal position, preferably 4-oxoretinol, inhibit growth of estrogen-receptor positive and estrogen-receptor negative breast cancer tumor cell lines and have utility for adjuvant therapy and treatment of metastatic disease.

US Patent:

59625341, Oct 5, 1999

Filed:

Jul 3, 1997

Appl. No.:

8/887633

Inventors:

Lorraine J. Gudas - New York NY
Charles Achkar - North Bergen NJ
Jochen Buck - New York NY
Alexander W. Langston - New York NY
Fadila Derguini - New York NY
Koji Nakanishi - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 3112
A61K 3111

US Classification:

514690

Abstract:

For the first time, certain retinoids with a side chain terminal CH. sub. 2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.

US Patent:

57863911, Jul 28, 1998

Filed:

Jan 11, 1995

Appl. No.:

8/371535

Inventors:

Lorraine J. Gudas - New York NY
Charles Achkar - North Bergen NJ
Jochen Buck - New York NY
Alexander W. Langston - New York NY
Fadila Derguini - New York NY
Koji Nakanishi - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY
The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 31115
A61K 31045
A61K 3108

US Classification:

514690

Abstract:

For the first time, certain retinoids with a side chain terminal CH. sub. 2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.

US Patent:

20170000840, Jan 5, 2017

Filed:

Dec 11, 2014

Appl. No.:

15/103389

Inventors:

- Ithaca NY, US
Lorraine Gudas - New York NY, US
Xiaohan Tang - Staten Island NY, US

International Classification:

A61K 38/06

Abstract:

The disclosure provides methods for preventing or treating oral cancers, and/or reducing the severity of symptoms of oral cancers. In particular, the present technology relates to administering an effective amount of an aromatic-cationic peptide to a subject in need thereof to normalize expression levels of genes involved in oral carcinogenesis.